Enanta Pharmaceuticals Inc (ENTA)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

500 ARSENAL STREET WATERTOWN, MA 02472

Enanta Pharmaceuticals, Inc., a biotechnology company, engages in the development of small molecule drugs for the infectious disease areas. Its product candidates include ABT-450, an inhibitor of NS3 protease that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV) infection; EDP-239, an NS5A Inhibitor for HCV infection; EDP-546, a Cyclophilin inhibitor, which is in preclinical studies for HCV infection treatment; and Nucleotide Polymerase inhibitor for HCV infection.

Data as of 2021-01-16
Market Cap938.088 Million Shares Outstanding20.079 Million Avg 30-day Volume164.086 Thousand
P/E Ratio-25.5 Dividend Yield EPS-1.83
Price/Sales13.42 Price cash flow ratio131.4 Price free cash flow ratio-150.5
Book Value22.69 Price to Tangible Book2.06 Alpha0.01
Short Interest Ratio % Short Interest to Float R-squared0.033921
BETA0.535289 52-week High/Low59.63 / 38.4 Stddev0.12789
View SEC Filings from ENTA instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 1 0.0% 1 (0.07%) 1 (0.06%) 0.0%
Funds Holding: 166 179 -7.26% 50 (3.29%) 54 (3.5%) -7.41%
13F shares: 18.622 Million 18.097 Million 2.9% 7.496 Million 7.024 Million 6.71%
% Ownership 92.7753 90.4649 2.55% 37.3429 35.1132 6.35%
New Positions: 15 39 -61.54% 4 16 -75.0%
Increased Positions 75 64 17.19% 25 17 47.06%
Closed Positions 23 14 64.29% 7 6 16.67%
Reduced Positions 54 52 3.85% 19 16 18.75%
Total Calls 1 32.607 Thousand -100.0% 4.1 Thousand
Total Puts 53.284 Thousand 59.601 Thousand -10.6% 34 Thousand 26 Thousand 30.77%
PUT/CALL Ratio 53,284.0 1.83 2911593.99% 6.34 840341.64%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ENTA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ENTA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

6 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

27.5 Thousand total shares from 6 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MELLETT PAUL J TREASURER AND CFO

  • Officer
61,759 2021-01-08 6

OR YAT SUN SR. VP & CSO

  • Officer
317,225 2020-12-15 3

LULY JAY R. PRESIDENT AND CEO

  • Officer
  • Director
681,488 2020-12-15 3

GARDINER NATHANIEL S. SR. VP & GENERAL COUNSEL

  • Officer
58,893 2020-12-15 6

ADDA NATHALIE SR. VP & CHIEF MEDICAL OFFICER

  • Officer
26,944 2020-12-15 3

KIEFFER TARA LYNN SR. VP, NEW PRODUCT DEV.

  • Officer
0 2020-12-07 2

FOLETTA MARK G

  • Director
0 2020-06-29 2

GOLUMBESKI GEORGE

  • Director
0 2020-02-26 1

VANCE TERRY

  • Director
0 2020-02-26 1

CARTER BRUCE L A

  • Director
0 2020-02-26 1

RUSSELL LESLEY

  • Director
0 2020-02-26 1

PETERSON KRISTINE

  • Director
0 2020-02-26 1

BUCKLEY STEPHEN JR.

  • Director
0 2019-02-28 0

OCAIN TIM SENIOR VICE PRESIDENT

  • Officer
17,547 2019-02-12 0

AFTING ERNST-GUENTER

  • Director
0 2016-02-11 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

MELLETT PAUL J - Officer TREASURER AND CFO

2021-01-08 20:57:13 -0500 2021-01-08 S 6,000 $45.58 d 61,759 direct yes 0.2677 -1.215 0.2677 2 -3.8921 3

GARDINER NATHANIEL S. - Officer SR. VP & GENERAL COUNSEL

2020-12-16 18:51:55 -0500 2020-12-15 M 5,250 d 0 direct

MELLETT PAUL J - Officer TREASURER AND CFO

2020-12-16 18:43:32 -0500 2020-12-15 M 2,625 d 0 direct

ADDA NATHALIE - Officer SR. VP & CHIEF MEDICAL OFFICER

2020-12-16 18:35:10 -0500 2020-12-15 M 5,250 d 0 direct

OR YAT SUN - Officer SR. VP & CSO

2020-12-16 18:27:09 -0500 2020-12-15 M 5,250 d 0 direct

LULY JAY R. - Director - Officer PRESIDENT AND CEO

2020-12-16 18:20:06 -0500 2020-12-15 M 7,500 d 0 direct

GARDINER NATHANIEL S. - Officer SR. VP & GENERAL COUNSEL

2020-12-16 18:51:55 -0500 2020-12-15 F 1,540 $42.52 d 42,248 direct 1.4036 -1.2885 1.4036 2 -2.6691 5

MELLETT PAUL J - Officer TREASURER AND CFO

2020-12-16 18:43:32 -0500 2020-12-15 F 770 $42.52 d 55,759 direct 1.4036 -1.2885 1.4036 2 -2.6691 5

ADDA NATHALIE - Officer SR. VP & CHIEF MEDICAL OFFICER

2020-12-16 18:35:10 -0500 2020-12-15 F 1,540 $42.52 d 26,944 direct 1.4036 -1.2885 1.4036 2 -2.6691 5

OR YAT SUN - Officer SR. VP & CSO

2020-12-16 18:27:09 -0500 2020-12-15 F 1,540 $42.52 d 317,225 direct 1.4036 -1.2885 1.4036 2 -2.6691 5

LULY JAY R. - Director - Officer PRESIDENT AND CEO

2020-12-16 18:20:06 -0500 2020-12-15 F 2,201 $42.52 d 681,488 direct 1.4036 -1.2885 1.4036 2 -2.6691 5

GARDINER NATHANIEL S. - Officer SR. VP & GENERAL COUNSEL

2020-12-16 18:51:55 -0500 2020-12-15 M 5,250 a 43,788 direct 1.4036 -1.2885 1.4036 2 -2.6691 5

MELLETT PAUL J - Officer TREASURER AND CFO

2020-12-16 18:43:32 -0500 2020-12-15 M 2,625 a 56,529 direct 1.4036 -1.2885 1.4036 2 -2.6691 5

ADDA NATHALIE - Officer SR. VP & CHIEF MEDICAL OFFICER

2020-12-16 18:35:10 -0500 2020-12-15 M 5,250 a 28,484 direct 1.4036 -1.2885 1.4036 2 -2.6691 5

OR YAT SUN - Officer SR. VP & CSO

2020-12-16 18:27:09 -0500 2020-12-15 M 5,250 a 318,765 direct 1.4036 -1.2885 1.4036 2 -2.6691 5

LULY JAY R. - Director - Officer PRESIDENT AND CEO

2020-12-16 18:20:06 -0500 2020-12-15 M 7,500 a 683,689 direct 1.4036 -1.2885 1.4036 2 -2.6691 5

KIEFFER TARA LYNN - Officer SR. VP, NEW PRODUCT DEV.

2020-12-08 19:16:32 -0500 2020-12-07 A 65,000 a 65,000 direct

GARDINER NATHANIEL S. - Officer SR. VP & GENERAL COUNSEL

2020-12-07 17:38:43 -0500 2020-12-03 M 1,667 $30.00 a 38,538 direct -0.3283 0.3986 11.7702 14.1618 24 -2.837 4

GARDINER NATHANIEL S. - Officer SR. VP & GENERAL COUNSEL

2020-12-07 17:38:43 -0500 2020-12-03 M 1,667 d 13,667 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments